Literature DB >> 30705417

Publisher Correction: Recent progress in broadly neutralizing antibodies to HIV.

Devin Sok1,2,3,4, Dennis R Burton5,6,7,8.   

Abstract

In the version of this article initially published, some of the references in Table 1 were incorrect. The correct references are as follows: in row 12, refs. 12,44 should be ref. 12; in row 16, refs. 2,17,27 should be ref. 109 (Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011)); in row 25, refs. 61,76 should be ref. 110 (Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010)); and in the bottom row, ref. 57 should be ref. 111 (Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012)). Those new references (109-111) should be included in the reference list. The errors have been corrected in the HTML and PDF versions of the article.

Entities:  

Year:  2019        PMID: 30705417     DOI: 10.1038/s41590-019-0329-x

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  3 in total

1.  GSK3732394: a Multi-specific Inhibitor of HIV Entry.

Authors:  David Wensel; Yongnian Sun; Jonathan Davis; Zhufang Li; Sharon Zhang; Thomas McDonagh; David Langley; Tracy Mitchell; Sebastien Tabruyn; Patrick Nef; Mark Cockett; Mark Krystal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

2.  Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.

Authors:  Sharana Mahomed; Nigel Garrett; Edmund Capparelli; Cheryl Baxter; Nonhlanhla Yende Zuma; Tanuja Gengiah; Derseree Archary; Penny Moore; Natasha Samsunder; Dan H Barouch; John Mascola; Julie Ledgerwood; Lynn Morris; Salim Abdool Karim
Journal:  BMJ Open       Date:  2019-07-03       Impact factor: 2.692

Review 3.  Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.

Authors:  Meredith Phelps; Alejandro Benjamin Balazs
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.